Measurement properties of the product of investigator’s global assessment and body surface area in children and adults with atopic dermatitis

Multiple clinician‐reported outcome measures exist for atopic dermatitis (AD) severity. However, there is no gold standard for use in clinical practice.

[1]  J. Silverberg,et al.  Validation of Patient‐Reported Outcomes Information System Sleep Disturbance and Sleep‐Related Impairment in adults with atopic dermatitis * , 2020, The British journal of dermatology.

[2]  A. Paller,et al.  Product of Investigator Global Assessment and body surface area (IGAxBSA): a practice-friendly alternative to the Eczema Area and Severity Index (EASI) to assess atopic dermatitis severity in children. , 2020, Journal of the American Academy of Dermatology.

[3]  A. Gottlieb,et al.  Exploration of the Product of the 5-Point Investigator’s Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis , 2019, Dermatology.

[4]  J. Silverberg,et al.  A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. , 2019, Journal of the American Academy of Dermatology.

[5]  J. Silverberg,et al.  Measurement properties of three assessments of burden used in atopic dermatitis in adults , 2018, The British journal of dermatology.

[6]  J. Silverberg,et al.  Patient-reported outcomes and quality of life measures in atopic dermatitis. , 2018, Clinics in dermatology.

[7]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  J. Silverberg,et al.  Severity strata for five patient‐reported outcomes in adults with atopic dermatitis , 2018, The British journal of dermatology.

[9]  J. Silverberg,et al.  Validation of patient‐reported global severity of atopic dermatitis in adults , 2018, Allergy.

[10]  H. Williams,et al.  Patient‐Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement , 2017, The British journal of dermatology.

[11]  C. Terwee,et al.  Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review , 2017, Allergy.

[12]  A. Armstrong,et al.  Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. , 2016, Journal of the American Academy of Dermatology.

[13]  Terry K Koo,et al.  A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. , 2016, Journal Chiropractic Medicine.

[14]  Å. Svensson,et al.  Usefulness of Rajka & Langeland Eczema Severity Score in Clinical Practice. , 2016, Acta dermato-venereologica.

[15]  H. Williams,et al.  A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. , 2016, Journal of the American Academy of Dermatology.

[16]  D. Murrell,et al.  A pilot comparison study of four clinician‐rated atopic dermatitis severity scales , 2015, The British journal of dermatology.

[17]  R. Fitzpatrick,et al.  Floor and ceiling effects in the OHS: an analysis of the NHS PROMs data set , 2015, BMJ Open.

[18]  E. Simpson,et al.  What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study , 2015, The British journal of dermatology.

[19]  J. Schmitt,et al.  Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME) , 2014, The British journal of dermatology.

[20]  Masutaka Furue,et al.  The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. , 2014, The Journal of allergy and clinical immunology.

[21]  Jochen Schmitt,et al.  Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. , 2013, The Journal of allergy and clinical immunology.

[22]  Daniel J Buysse,et al.  Development of Short Forms From the PROMIS™ Sleep Disturbance and Sleep-Related Impairment Item Banks , 2012, Behavioral sleep medicine.

[23]  C. Terwee,et al.  Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist , 2011, Quality of Life Research.

[24]  A. Armstrong,et al.  Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010 , 2011, PloS one.

[25]  A. Finlay,et al.  The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results , 2008, The British journal of dermatology.

[26]  Suephy C. Chen,et al.  A pilot quality-of-life instrument for pruritus. , 2008, Journal of the American Academy of Dermatology.

[27]  H. Williams,et al.  The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. , 2004, Archives of dermatology.

[28]  R. Chervin.  Epworth sleepiness scale? , 2003, Sleep medicine.

[29]  David J. Hand,et al.  A Simple Generalisation of the Area Under the ROC Curve for Multiple Class Classification Problems , 2001, Machine Learning.

[30]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.

[31]  C. Dancey,et al.  Statistics Without Maths For Psychology , 1999 .

[32]  M. Johns,et al.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale. , 1991, Sleep.

[33]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[34]  C. Metz.  Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.

[35]  A. Trickey,et al.  The European Academy of Dermatology and Venereology Congress , 2015 .

[36]  Laura Antolini,et al.  Computational Statistics and Data Analysis Finding the Optimal Cut-point for Gaussian and Gamma Distributed Biomarkers , 2022 .

[37]  C. Terwee,et al.  Quality criteria were proposed for measurement properties of health status questionnaires. , 2007, Journal of clinical epidemiology.

[38]  M. Graeber,et al.  The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. , 2001, Experimental dermatology.

[39]  J. Ring,et al.  Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. , 1997, Dermatology.

[40]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .

[41]  A. Taïeb,et al.  Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. , 1993, Dermatology.